Lucia Kulhavy, PA
Medical · Roanoke, VANPI 1225099773
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (47.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Novartis at 55.3% of the total. Among medical clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $38.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Lilly USA, LLC$231
- Pfizer$185
- Johnson & Johnson$171
- Daiichi Sankyo Inc.$136
- Bristol Myers Squibb$125
- plus $2K from 32 others
What the payments were for
- Food & beverage$2,52045%
- Education$3907%
- Other$2,63247%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 52 | $3,064 |
| Lilly USA, LLC | 4 | $231 |
| Pfizer | 9 | $185 |
| Johnson & Johnson | 4 | $171 |
| Daiichi Sankyo Inc. | 6 | $136 |
| Bristol Myers Squibb | 6 | $125 |
| Genentech USA, Inc. | 1 | $118 |
| AbbVie | 5 | $113 |
| E.r. Squibb & Sons, L.L.C. | 3 | $106 |
| GE HealthCare | 1 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $92 |
| Ipsen Biopharmaceuticals, Inc | 4 | $86 |
| Astellas Pharma US Inc | 3 | $83 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $80 |
| Pharmacosmos Therapeutics Inc. | 3 | $77 |
| AstraZeneca | 4 | $76 |
| Eisai Inc. | 3 | $61 |
| Coherus Oncology, Inc. | 2 | $55 |
| Puma Biotechnology, Inc. | 3 | $51 |
| Accord Healthcare, Inc. | 2 | $45 |
| Servier Pharmaceuticals LLC | 2 | $41 |
| Novocure Inc. | 2 | $37 |
| Merck | 2 | $37 |
| Exelixis Inc. | 2 | $36 |
| Myriad Genetic Laboratories, Inc. | 2 | $36 |
| Taiho Oncology, Inc. | 1 | $33 |
| Stemline Therapeutics Inc. | 1 | $28 |
| Seagen Inc. | 1 | $26 |
| Immunocore Limited | 1 | $26 |
| Boehringer Ingelheim | 1 | $24 |
| Amgen | 1 | $24 |
| Gilead | 1 | $24 |
| Legend Biotech USA Inc. | 1 | $21 |
| Beone Medicines USA, Inc. | 1 | $21 |
| Genmab U.S., Inc. | 1 | $20 |
| Pharmaessentia USA Corporation | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| ADC Therapeutics America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Venclexta$118
How this compares
$5,542 in reported general payments places this provider in the 90th percentile of 632 medical providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 60 | $49,835 |
| Fentanyl | 15 | $2,992 |
| Hydrocortisone | 12 | $875 |
| Ondansetron OdtOndansetron | 49 | $742 |
| Levofloxacin | 11 | $515 |
| Olanzapine | 48 | $499 |
| Oxycodone Hcl | 25 | $453 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 24 | $313 |
| Prednisone | 61 | $293 |
| Hydroxyurea | 16 | $256 |
| Potassium Chloride | 29 | $228 |
| Tramadol Hcl | 13 | $196 |
| Prochlorperazine Maleate | 13 | $182 |
| Levothyroxine Sodium | 19 | $119 |
| Duloxetine Hcl | 19 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $185 | $49,83560 claims |
| Lilly USA, LLCOlanzapine | $231 | $49948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 632 medical providers in Virginia.
Other medical in Roanoke
- Erin MyersRoanoke$14K
- Jason BaileyRoanoke$10K
- Dennis DuncanRoanoke$8K
- Bryan UrquhartFredericksburg$264K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Brian LamFalls Church$42K
- Christine KesslerKing George$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.